| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 28 | 2023 | 6550 | 1.850 |
Why?
|
| Graft vs Host Disease | 17 | 2023 | 2638 | 1.830 |
Why?
|
| Leukemia, Myeloid, Acute | 27 | 2024 | 6915 | 1.590 |
Why?
|
| Transplantation Conditioning | 13 | 2022 | 2238 | 1.320 |
Why?
|
| Myelodysplastic Syndromes | 13 | 2023 | 2979 | 1.280 |
Why?
|
| HLA-A2 Antigen | 5 | 2018 | 159 | 1.230 |
Why?
|
| Cyclophosphamide | 11 | 2022 | 3001 | 1.230 |
Why?
|
| T-Lymphocytes, Cytotoxic | 10 | 2021 | 1016 | 1.180 |
Why?
|
| Leukocyte Elastase | 3 | 2012 | 70 | 0.950 |
Why?
|
| Myeloblastin | 3 | 2012 | 64 | 0.940 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 2019 | 675 | 0.910 |
Why?
|
| Transplantation, Homologous | 10 | 2023 | 2843 | 0.880 |
Why?
|
| Antigens, Neoplasm | 5 | 2012 | 1506 | 0.830 |
Why?
|
| Hematologic Neoplasms | 5 | 2022 | 1870 | 0.740 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2019 | 219 | 0.730 |
Why?
|
| Immunotherapy | 8 | 2023 | 3341 | 0.720 |
Why?
|
| Busulfan | 6 | 2023 | 764 | 0.710 |
Why?
|
| Cross-Priming | 3 | 2018 | 39 | 0.700 |
Why?
|
| B7-H1 Antigen | 2 | 2016 | 1022 | 0.640 |
Why?
|
| Peptide Fragments | 4 | 2018 | 1271 | 0.590 |
Why?
|
| Vidarabine | 6 | 2021 | 1341 | 0.580 |
Why?
|
| Leukemia, Myeloid | 2 | 2011 | 941 | 0.550 |
Why?
|
| Multiple Myeloma | 4 | 2023 | 2138 | 0.500 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 1375 | 0.490 |
Why?
|
| Peptides | 5 | 2019 | 1479 | 0.490 |
Why?
|
| Chimerism | 1 | 2014 | 63 | 0.480 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2023 | 1763 | 0.460 |
Why?
|
| Cathepsin G | 1 | 2012 | 23 | 0.450 |
Why?
|
| CTLA-4 Antigen | 1 | 2016 | 657 | 0.430 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2011 | 110 | 0.390 |
Why?
|
| Cancer Vaccines | 3 | 2011 | 697 | 0.390 |
Why?
|
| Myeloablative Agonists | 3 | 2022 | 384 | 0.360 |
Why?
|
| Granulocytes | 1 | 2010 | 224 | 0.360 |
Why?
|
| Humans | 66 | 2024 | 261506 | 0.340 |
Why?
|
| Skin Neoplasms | 4 | 2022 | 4654 | 0.340 |
Why?
|
| Antigen-Presenting Cells | 3 | 2018 | 284 | 0.340 |
Why?
|
| Peptide Hydrolases | 1 | 2010 | 256 | 0.330 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.330 |
Why?
|
| Transplantation, Haploidentical | 4 | 2022 | 125 | 0.310 |
Why?
|
| Leukemia | 2 | 2015 | 1635 | 0.300 |
Why?
|
| 5-Methoxytryptamine | 1 | 2006 | 1 | 0.290 |
Why?
|
| Blood Platelets | 1 | 2011 | 731 | 0.280 |
Why?
|
| Aged | 26 | 2023 | 70117 | 0.280 |
Why?
|
| Middle Aged | 29 | 2023 | 86204 | 0.270 |
Why?
|
| Rhabdomyolysis | 1 | 2006 | 52 | 0.270 |
Why?
|
| Hallucinogens | 1 | 2006 | 48 | 0.260 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 2002 | 136 | 0.260 |
Why?
|
| Unrelated Donors | 2 | 2018 | 304 | 0.260 |
Why?
|
| Epitopes | 3 | 2012 | 685 | 0.260 |
Why?
|
| Adult | 26 | 2023 | 77950 | 0.250 |
Why?
|
| Interferon-alpha | 2 | 2010 | 889 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 15862 | 0.250 |
Why?
|
| Cell Line, Tumor | 7 | 2019 | 14551 | 0.250 |
Why?
|
| Myeloproliferative Disorders | 2 | 2022 | 767 | 0.250 |
Why?
|
| Tacrolimus | 2 | 2022 | 335 | 0.240 |
Why?
|
| Disease-Free Survival | 7 | 2019 | 10001 | 0.240 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 1215 | 0.240 |
Why?
|
| Sulfonamides | 2 | 2023 | 1823 | 0.230 |
Why?
|
| Isoflavones | 1 | 2023 | 72 | 0.230 |
Why?
|
| Siblings | 2 | 2022 | 285 | 0.230 |
Why?
|
| Interleukin-12 | 1 | 2004 | 253 | 0.220 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 2265 | 0.220 |
Why?
|
| Interferon Type I | 1 | 2024 | 250 | 0.220 |
Why?
|
| Male | 26 | 2023 | 123000 | 0.220 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2018 | 589 | 0.210 |
Why?
|
| Female | 28 | 2023 | 141928 | 0.210 |
Why?
|
| Melanoma | 2 | 2012 | 5317 | 0.200 |
Why?
|
| Killer Cells, Natural | 2 | 2010 | 904 | 0.200 |
Why?
|
| Antigens, CD | 2 | 2021 | 1385 | 0.200 |
Why?
|
| Oxidative Phosphorylation | 2 | 2023 | 253 | 0.200 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.200 |
Why?
|
| Remission Induction | 6 | 2021 | 3569 | 0.200 |
Why?
|
| Immunophenotyping | 4 | 2019 | 1681 | 0.190 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 51 | 0.190 |
Why?
|
| Monitoring, Immunologic | 1 | 2021 | 47 | 0.190 |
Why?
|
| Immune Evasion | 1 | 2021 | 73 | 0.190 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2011 | 2390 | 0.190 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2021 | 1146 | 0.190 |
Why?
|
| Graft vs Leukemia Effect | 2 | 2011 | 105 | 0.180 |
Why?
|
| Protein Transport | 2 | 2012 | 734 | 0.180 |
Why?
|
| Cystitis | 1 | 2021 | 107 | 0.180 |
Why?
|
| Bone Marrow | 7 | 2023 | 2358 | 0.180 |
Why?
|
| Treatment Outcome | 12 | 2023 | 32848 | 0.170 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2023 | 923 | 0.170 |
Why?
|
| Histocompatibility Testing | 2 | 2018 | 447 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2021 | 582 | 0.170 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2019 | 18 | 0.170 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 862 | 0.170 |
Why?
|
| DNA-Binding Proteins | 2 | 2021 | 4821 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5319 | 0.170 |
Why?
|
| Mice | 11 | 2023 | 34495 | 0.170 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 305 | 0.170 |
Why?
|
| Allografts | 3 | 2015 | 650 | 0.170 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 3472 | 0.170 |
Why?
|
| Survival Analysis | 6 | 2020 | 9180 | 0.170 |
Why?
|
| Survival Rate | 7 | 2021 | 12221 | 0.160 |
Why?
|
| Leukemic Infiltration | 1 | 2018 | 72 | 0.160 |
Why?
|
| Glycosylation | 1 | 2019 | 213 | 0.160 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2019 | 157 | 0.160 |
Why?
|
| Prognosis | 9 | 2022 | 21713 | 0.160 |
Why?
|
| Interleukin-2 | 1 | 2002 | 842 | 0.160 |
Why?
|
| Acute Disease | 4 | 2022 | 2422 | 0.160 |
Why?
|
| Complement Activation | 1 | 2018 | 94 | 0.160 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 10331 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 8873 | 0.150 |
Why?
|
| Mutation | 3 | 2021 | 15179 | 0.150 |
Why?
|
| Antigen Presentation | 1 | 2018 | 272 | 0.150 |
Why?
|
| Dendritic Cells | 4 | 2022 | 1085 | 0.150 |
Why?
|
| Young Adult | 10 | 2022 | 21445 | 0.150 |
Why?
|
| T-Lymphocytes | 3 | 2022 | 3869 | 0.150 |
Why?
|
| Receptors, Immunologic | 1 | 2018 | 309 | 0.150 |
Why?
|
| Phosphoproteins | 1 | 2022 | 1152 | 0.150 |
Why?
|
| Biological Transport | 1 | 2018 | 597 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 895 | 0.140 |
Why?
|
| Immunomodulation | 1 | 2018 | 242 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2010 | 5270 | 0.140 |
Why?
|
| Stem Cell Transplantation | 3 | 2021 | 1360 | 0.140 |
Why?
|
| Lymphocyte Activation | 2 | 2019 | 1688 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2002 | 2450 | 0.130 |
Why?
|
| Retrospective Studies | 9 | 2023 | 37905 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 3 | 2016 | 4367 | 0.130 |
Why?
|
| Neoplasms | 3 | 2021 | 15193 | 0.130 |
Why?
|
| Prospective Studies | 5 | 2021 | 12873 | 0.130 |
Why?
|
| Animals | 11 | 2023 | 59536 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 1048 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 2 | 2021 | 1581 | 0.130 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 1656 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2018 | 649 | 0.120 |
Why?
|
| Cytogenetics | 1 | 2014 | 149 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 11538 | 0.120 |
Why?
|
| Recurrence | 4 | 2023 | 4758 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2021 | 2218 | 0.120 |
Why?
|
| Breast Neoplasms | 3 | 2012 | 15694 | 0.120 |
Why?
|
| Incidence | 2 | 2021 | 5673 | 0.120 |
Why?
|
| Adolescent | 8 | 2021 | 31252 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1350 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3821 | 0.110 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2012 | 141 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 3 | 2012 | 5395 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2004 | 2326 | 0.100 |
Why?
|
| HLA Antigens | 1 | 2014 | 546 | 0.100 |
Why?
|
| Lymphocyte Depletion | 1 | 2012 | 264 | 0.100 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2011 | 109 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2012 | 235 | 0.100 |
Why?
|
| Antigens, CD34 | 1 | 2012 | 593 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1077 | 0.100 |
Why?
|
| Tissue Donors | 3 | 2022 | 769 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2004 | 3022 | 0.090 |
Why?
|
| Databases, Genetic | 1 | 2014 | 745 | 0.090 |
Why?
|
| Vaccines, DNA | 1 | 2011 | 105 | 0.090 |
Why?
|
| Complement System Proteins | 1 | 2011 | 139 | 0.090 |
Why?
|
| CD52 Antigen | 1 | 2009 | 46 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6207 | 0.090 |
Why?
|
| Immunotherapy, Active | 1 | 2010 | 46 | 0.090 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 423 | 0.090 |
Why?
|
| Lysosomes | 1 | 2012 | 347 | 0.090 |
Why?
|
| Ubiquitination | 1 | 2012 | 575 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 254 | 0.090 |
Why?
|
| Antibodies | 1 | 2012 | 838 | 0.090 |
Why?
|
| Antigens, CD20 | 1 | 2009 | 206 | 0.090 |
Why?
|
| Lymphocyte Transfusion | 1 | 2010 | 175 | 0.080 |
Why?
|
| Aminoglycosides | 1 | 2010 | 220 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2011 | 9244 | 0.080 |
Why?
|
| Amino Acid Sequence | 2 | 2012 | 4233 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 986 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 419 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2011 | 1163 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2021 | 6869 | 0.080 |
Why?
|
| Cytokines | 2 | 2010 | 2809 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2022 | 11965 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 29902 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 4053 | 0.080 |
Why?
|
| Biomarkers | 1 | 2019 | 5047 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 1678 | 0.070 |
Why?
|
| Child | 4 | 2022 | 29154 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 7222 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 864 | 0.070 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 14289 | 0.070 |
Why?
|
| Risk Factors | 2 | 2021 | 17523 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 1242 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2011 | 1234 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2054 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 1294 | 0.070 |
Why?
|
| Neutropenia | 1 | 2010 | 968 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2009 | 747 | 0.070 |
Why?
|
| Protein Binding | 1 | 2012 | 3438 | 0.070 |
Why?
|
| Lymphocyte Count | 2 | 2018 | 486 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 3552 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 14889 | 0.070 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 2 | 2002 | 107 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 3719 | 0.070 |
Why?
|
| Diuretics | 1 | 2006 | 170 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 1586 | 0.060 |
Why?
|
| Fluid Therapy | 1 | 2006 | 182 | 0.060 |
Why?
|
| Rituximab | 1 | 2009 | 1528 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2023 | 1144 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 334 | 0.060 |
Why?
|
| Haplotypes | 2 | 2018 | 856 | 0.060 |
Why?
|
| Genotype | 1 | 2011 | 4109 | 0.060 |
Why?
|
| Genome, Human | 1 | 2011 | 1869 | 0.060 |
Why?
|
| Erythroid Precursor Cells | 1 | 2022 | 61 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 8865 | 0.050 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2002 | 35 | 0.050 |
Why?
|
| Purines | 1 | 2023 | 273 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2330 | 0.050 |
Why?
|
| Electron Transport Complex I | 1 | 2022 | 62 | 0.050 |
Why?
|
| RNA Splicing Factors | 1 | 2022 | 153 | 0.050 |
Why?
|
| Donor Selection | 1 | 2022 | 110 | 0.050 |
Why?
|
| RNA Stability | 1 | 2002 | 125 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2022 | 148 | 0.050 |
Why?
|
| Granzymes | 1 | 2021 | 91 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2024 | 842 | 0.050 |
Why?
|
| eIF-2 Kinase | 1 | 2022 | 164 | 0.050 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2022 | 106 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 1290 | 0.050 |
Why?
|
| Cell Line | 2 | 2024 | 5114 | 0.050 |
Why?
|
| Dioxygenases | 1 | 2021 | 159 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2024 | 584 | 0.050 |
Why?
|
| Receptor, Notch1 | 1 | 2022 | 218 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2021 | 234 | 0.050 |
Why?
|
| Glutamine | 1 | 2022 | 299 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2023 | 577 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2023 | 669 | 0.050 |
Why?
|
| Mothers | 1 | 2022 | 410 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2020 | 6100 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 4988 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 4549 | 0.040 |
Why?
|
| Infant | 1 | 2015 | 13310 | 0.040 |
Why?
|
| Methotrexate | 1 | 2022 | 999 | 0.040 |
Why?
|
| Kinetics | 1 | 2002 | 2049 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 905 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2018 | 1987 | 0.040 |
Why?
|
| Genes, cdc | 1 | 2018 | 81 | 0.040 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 2527 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 2927 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 3251 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2015 | 16273 | 0.040 |
Why?
|
| Disease Progression | 1 | 2009 | 6682 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 470 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 3230 | 0.040 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2022 | 426 | 0.040 |
Why?
|
| Nucleotides | 1 | 2018 | 164 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 1070 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 5539 | 0.040 |
Why?
|
| Comorbidity | 1 | 2023 | 2352 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 1005 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 4744 | 0.040 |
Why?
|
| Melphalan | 1 | 2019 | 834 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2018 | 305 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2002 | 984 | 0.030 |
Why?
|
| Ligands | 1 | 2018 | 995 | 0.030 |
Why?
|
| Gene Expression | 1 | 2004 | 3570 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2018 | 560 | 0.030 |
Why?
|
| Azacitidine | 1 | 2021 | 1149 | 0.030 |
Why?
|
| Glycolysis | 1 | 2018 | 519 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2002 | 6150 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2002 | 1248 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 7548 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 943 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 2292 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 10035 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 1489 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 2864 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 1859 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2018 | 992 | 0.030 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2011 | 51 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 3639 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 1282 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2011 | 102 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2011 | 211 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 360 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 1399 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 1960 | 0.020 |
Why?
|
| Leukocytes | 1 | 2011 | 422 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 568 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2011 | 665 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 1082 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5178 | 0.020 |
Why?
|
| Phenotype | 1 | 2018 | 6295 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 2314 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 1869 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 4917 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 6089 | 0.020 |
Why?
|
| Stem Cells | 1 | 2011 | 1213 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2010 | 3033 | 0.010 |
Why?
|
| Cell Movement | 1 | 2010 | 2466 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 5637 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 13658 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 1618 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2002 | 1519 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2002 | 1313 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 891 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 2315 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2002 | 1547 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2002 | 3005 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 3981 | 0.010 |
Why?
|
| United States | 1 | 2011 | 15433 | 0.010 |
Why?
|